Clinical Trials
2 trialsNCT05773092 2025-09-03
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT02631460 2015-12-16
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
Sun Yat-sen University
Phase 2 Unknown